Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy

Hyo Suk Lee, Byung Chul Yoo, Kwan Sik Lee, Ju Hyun Kim, Soon Ho Um, Soo Hyung Ryu, Young Suk Lee, Young Soo Kim, Kwon Yoo, Joon Yeol Han, Jae Seok Hwang, Tae Hun Kim, Jin Mo Yang, Heon Ju Lee, Chae Yoon Chon, Mong Cho, Byung Hoon Han, Seong Gyu Hwang, Kwan Soo Byun, Young Hwa ChungSe Hyun Cho, Kwang Cheol Koh, Byung Ik Kim, Haak Cheoul Kim, Seung Woon Paik, Myung Seok Lee, Hee Won Yoo, Cheol Ju Han

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background: This study was conducted to evaluate the durability of clevudine-induced viral response after the withdrawal of treatment. Methods: Patients who showed a complete response [alanine aminotransferase (ALT) normalization and hepatitis B virus (HBV) DNA <4,700 copies/mL for hepatitis B envelope antigen (HBeAg)-negative patients; ALT normalization, HBV DNA <4,700 copies/mL, and HBeAg seroconversion for HBeAg-positive patients] in the previous clevudine phase III trials were followed for an additional 96 weeks without any treatment for hepatitis B. Results: Of the 63 patients in the study cohort, 73% and 35% of the patients had HBV DNA <141,500 and <4,700 copies/mL, respectively, and 75% of the patients had normal ALT at the end of follow-up. HBeAg seroconversion was maintained in 81% of the patients and hepatitis B surface antigen (HBsAg) loss occurred in 3 patients. Continued HBsAg titer decrease (-0.5 log IU/mL) was observed in the sustained viral responders, suggesting the reduction of covalently closed circular DNA in hepatocytes. Conclusions: The clevudine-induced viral response was durable in the majority of patients for 2 years after the withdrawal of treatment.

Original languageEnglish
Pages (from-to)410-414
Number of pages5
JournalJournal of Gastroenterology
Issue number3
StatePublished - Mar 2011

Bibliographical note

Funding Information:
This study was sponsored by Bukwang Pharmaceutical Co. Ltd and in part by the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (Grant No. 02-PJ2-PG4-PT01-0034).


  • HBeAg seroconversion
  • HBsAg loss
  • Hepatitis B virus
  • ccc-DNA


Dive into the research topics of 'Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy'. Together they form a unique fingerprint.

Cite this